Rezetapopt showed a 44.4% response rate and durable responses over 8 months in ovarian cancer with p53 Y220C mutation, with mostly mild side effects.
Dr. Alison Schram
Advertisement
Gynecologic Oncologist at Memorial Sloan Kettering Cancer Center.
Articles by Dr. Alison Schram
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CURE
1
Top 5 Takeaways From ASCO 2026 That Patients Should Know
2
Uterine Cancer Story: From Emergency Surgery to Pelvic Radiation Recovery
3
When Insurance Says No: How Patients Can Fight Back Against Cancer Treatment Denials
4
26 Years of Resilience: Overcoming Rare Blood Cancer and Severe GVHD
5